Vehicle Gel

( DrugBank: - / KEGG DRUG: - )

2 diseases

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	1

ID	Disease name (Link within this page)	Number of trials
34	Neurofibromatosis	2

13. Multiple sclerosis/Neuromyelitis optica

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02568111 (ClinicalTrials.gov)	February 2016	1/10/2015	Brimonidine Tartrate for the Treatment of Injection Related Erythema	Brimonidine Tartrate for the Treatment of Injection Related Erythema Associated With Sub-cutaneous A ...	Relapsing-Remitting Multiple Sclerosis (RRMS)	Drug: peginterferon beta-1a;Drug: brimonidine tartrate;Drug: Vehicle Gel	Biogen	NULL	Withdrawn	18 Years	N/A	Both	0	Phase 4	NULL

Clinical trials : 133 / Drugs : 186 - (DrugBank : 67) / Drug target genes : 79 - Drug target pathways : 190

trials per page:

Showing 1 to 2 of 2 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05005845 (ClinicalTrials.gov)	September 20, 2021	2/8/2021	NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas ...	A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2 Dose-Response Study to Determ ...	Cutaneous Neurofibroma;Neurofibromatosis 1	Drug: NFX-179 gel;Drug: Vehicle gel	NFlection Therapeutics, Inc.	NULL	Active, not recruiting	18 Years	N/A	All	199	Phase 2	United States
2	NCT04435665 (ClinicalTrials.gov)	August 21, 2020	8/6/2020	NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas ( ...	A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2a Study to Determine Safety, T ...	Neurofibromatosis 1;Cutaneous Neurofibroma	Drug: NFX-179 Gel;Drug: Vehicle Gel	NFlection Therapeutics, Inc.	NULL	Completed	18 Years	N/A	All	48	Phase 2	United States